[go: up one dir, main page]

NO963508D0 - Ureasebasert vaksine og behandling av Heliobacter infeksjon - Google Patents

Ureasebasert vaksine og behandling av Heliobacter infeksjon

Info

Publication number
NO963508D0
NO963508D0 NO963508A NO963508A NO963508D0 NO 963508 D0 NO963508 D0 NO 963508D0 NO 963508 A NO963508 A NO 963508A NO 963508 A NO963508 A NO 963508A NO 963508 D0 NO963508 D0 NO 963508D0
Authority
NO
Norway
Prior art keywords
urea
treatment
based vaccine
heliobacter infection
heliobacter
Prior art date
Application number
NO963508A
Other languages
English (en)
Other versions
NO963508L (no
Inventor
Pierre Michetti
Irene Corthesy-Theulaz
Andre Blum
Catherine Davin
Rainer Haas
Jean-Pierre Kraehenbuhl
Emilia Saraga
Original Assignee
Oravax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oravax Inc filed Critical Oravax Inc
Publication of NO963508D0 publication Critical patent/NO963508D0/no
Publication of NO963508L publication Critical patent/NO963508L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO963508A 1994-02-23 1996-08-22 Urease-basert vaksine og behandling av Helicobacter-infeksjon NO963508L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/200,346 US6290962B1 (en) 1992-11-03 1994-02-23 Urease-based vaccine and treatment for helicobacter infection
PCT/US1995/002202 WO1995022987A1 (en) 1994-02-23 1995-02-23 Urease-based vaccine and treatment for helicobacter infection

Publications (2)

Publication Number Publication Date
NO963508D0 true NO963508D0 (no) 1996-08-22
NO963508L NO963508L (no) 1996-10-21

Family

ID=22741337

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963508A NO963508L (no) 1994-02-23 1996-08-22 Urease-basert vaksine og behandling av Helicobacter-infeksjon

Country Status (15)

Country Link
US (2) US6290962B1 (no)
EP (1) EP0751786A4 (no)
JP (1) JPH09509661A (no)
AU (1) AU694195C (no)
BR (1) BR9506884A (no)
CA (1) CA2184057A1 (no)
CZ (1) CZ250396A3 (no)
FI (1) FI963281L (no)
HU (1) HUT75374A (no)
NO (1) NO963508L (no)
NZ (1) NZ282535A (no)
OA (1) OA10372A (no)
PL (1) PL179149B1 (no)
SK (1) SK109496A3 (no)
WO (1) WO1995022987A1 (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2154063C (en) * 1993-07-27 2006-11-21 Christopher Vincent Doidge Treatment of h. pylori associated gastroduodenal disease
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
HUP9801266A3 (en) * 1995-04-28 1999-07-28 Oravax Inc Cambridge Multimeric, recombinant urease vaccine
EP0862458A1 (en) * 1995-10-09 1998-09-09 Cortecs International Limited Urease for the treatment of helicobacter pylori infections
GB2307987A (en) * 1995-12-06 1997-06-11 Univ Manchester Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto
SE9600647D0 (sv) * 1996-02-21 1996-02-21 Bror Morein Ny användning
ATE203678T1 (de) * 1996-04-15 2001-08-15 Anton Prof Dr Med Vet Dr Mayr Verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren zur herstellung von arzneimitteln
WO1997039764A1 (fr) * 1996-04-23 1997-10-30 Toray Industries, Inc. Agent anti-pylori
EP0909272B1 (en) * 1996-06-10 2007-02-07 Borén, Thomas Helicobacter pylori adhesin binding group antigen
US6248551B1 (en) * 1997-03-28 2001-06-19 Institut Pasteur Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides
US20020026035A1 (en) * 1997-04-01 2002-02-28 Harold Kleanthous Helicobacter ghpo 1360 and ghpo 750 polypeptides and corresponding polynucleotide molecules
JP3430853B2 (ja) * 1997-04-11 2003-07-28 株式会社ゲン・コーポレーション 胃炎、胃潰瘍および十二指腸潰瘍の予防剤並びに治療剤
CA2287976A1 (fr) * 1997-04-30 1998-11-05 Bruno Guy Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1
FR2762788B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter pour usage par voie systemique sous-diaphragmatique
FR2762787B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1
US20030158396A1 (en) * 1997-07-29 2003-08-21 Harold Kleanthous Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
US6599509B2 (en) * 1997-09-02 2003-07-29 Massachusetts Institute Of Technology Compositions and methods comprising helicobacter antigens for treatment and prevention of inflammatory bowel disease
US5985631A (en) 1997-09-12 1999-11-16 Oravax-Merieux Co. Method for preventing the activation of inactive, recombinant Helicobacter pylori apourease
US20020151462A1 (en) * 1998-02-19 2002-10-17 Ling Lissolo Helicobacter pylori membrane proteins
GB9807721D0 (en) * 1998-04-08 1998-06-10 Chiron Spa Antigen
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
JP2002518343A (ja) 1998-06-19 2002-06-25 メリウクス オラバクス ヘリコバクター感染に対する非経口的免疫処置法におけるｌｔおよびｃｔ
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
US7041296B1 (en) * 1999-11-12 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating inflammatory bowel disease using cholera toxin B subunit
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CA2351110A1 (en) * 2000-07-17 2002-01-17 Akzo Nobel N.V. Helicobacter felis vaccine
EP1404368B1 (en) * 2001-06-07 2009-12-09 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
CA2449670A1 (en) * 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
MXPA04004726A (es) * 2001-11-19 2004-07-30 Becton Dickinson Co Composiciones farmaceuticas en forma particulada.
US7357949B2 (en) * 2001-12-21 2008-04-15 Agion Technologies Inc. Encapsulated inorganic antimicrobial additive for controlled release
US20030118658A1 (en) * 2001-12-21 2003-06-26 Trogolo Jeffrey A. High aspect ratio encapsulated inorganic antimicrobial additive for controlled release
FR2837835B1 (fr) * 2002-03-29 2007-06-22 Maria Urdaci Souche bacillus subtilis cu1, son utilisation comme agent immunomodulateur du systeme immunitaire et vaccin recombinant vivant contre h. pylori la contenant
CN1212126C (zh) * 2002-07-09 2005-07-27 中国科学院长春应用化学研究所 纳米羟基磷灰石补钙剂
JP2004041084A (ja) * 2002-07-11 2004-02-12 Japan Science & Technology Corp ヘリコバクター・ピロリ菌に対するワクチン用ペプチド、それをコードする遺伝子、その遺伝子が導入された形質転換体、及びそれらの利用方法
MXPA05000778A (es) * 2002-07-18 2005-08-29 Helix Biopharma Corp Uso de ureasa para inhibir el crecimiento de celulas cancerosas.
US7264800B2 (en) 2002-07-18 2007-09-04 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
US20040109905A1 (en) * 2002-09-18 2004-06-10 Debasis Bagchi Method and composition of anthocyanin-rich berry extracts that prevents or inhibits angiogenesis and helicobacter pylori and acts as a powerful antioxidant that provides various health benefits
US20070258901A1 (en) * 2004-08-04 2007-11-08 Ursula Boschert Capsules Containing Transiently Transfected Cells, Method for Preparing Same and Uses Thereof
US8029777B2 (en) 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
WO2006015445A1 (en) * 2004-08-13 2006-02-16 Marshall Barry J Bacterial delivery system
WO2008055316A1 (en) * 2006-11-10 2008-05-15 Marshall Barry J Methods and devices for the delivery of peptides into the gastric mucosa
PL218700B1 (pl) 2012-03-29 2015-01-30 Gdański Univ Medyczny Doustna szczepionka zawierająca przetrwalniki Bacillus subtilis oraz jej zastosowanie do immunizacji przeciwko Helicobacter pylori
CN103461685B (zh) * 2012-06-07 2014-10-22 中国农业科学院北京畜牧兽医研究所 瘤胃脲酶抗原组合物及其制备方法和应用及瘤胃脲酶抗原蛋白的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268278A (en) * 1984-03-30 1993-12-07 Istituto Farmacologico Serono S.P.A. Genetic expression of somatostatin as hybrid polypeptide
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5268276A (en) * 1988-09-16 1993-12-07 Jan Holmgren Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
FR2637612B1 (fr) * 1988-10-06 1993-09-10 Pasteur Institut Sequences de nucleotides codant pour une proteine a activite ureasique
US5443832A (en) 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
US5859219A (en) 1992-02-26 1999-01-12 Vanderbilt University Purified vacuolating toxin from Helicobacter pylori and methods to use same
ATE273021T1 (de) 1992-02-26 2004-08-15 Univ Vanderbilt Gereinigtes vakuolisierendes toxin aus helicobacter pylori und methoden zu dessen verwendung
WO1993018150A1 (en) * 1992-03-02 1993-09-16 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
ES2111625T3 (es) * 1992-07-06 1998-03-16 Nestle Sa Agente antigastritis.
US5403924A (en) 1992-10-13 1995-04-04 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration
US5733740A (en) 1992-10-13 1998-03-31 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
US5972336A (en) 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
CA2154063C (en) 1993-07-27 2006-11-21 Christopher Vincent Doidge Treatment of h. pylori associated gastroduodenal disease
AUPM612494A0 (en) * 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
DE19521314A1 (de) * 1995-06-12 1996-12-19 Max Planck Gesellschaft Adhärenzgen aus Helicobacter pylori und davon codiertes Polypeptid
DE19521312A1 (de) * 1995-06-12 1996-12-19 Max Planck Gesellschaft Verfahren zur Identifizierung sekretorischer Gene aus Helicobacter pylori
DE19535321A1 (de) * 1995-09-22 1997-03-27 Max Planck Gesellschaft Neues Adhäsin aus Helicobacter pylori
GB2307987A (en) * 1995-12-06 1997-06-11 Univ Manchester Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto
FR2745186B1 (fr) * 1996-02-26 1998-12-31 Torossian Fernand Narbey Complexe immunomodulateur et ses utilisations pour le traitement et la prevention des recidives des affections par helicobacter
US6060241A (en) * 1996-04-05 2000-05-09 Kieta Holding Sa Compositions and methods relating to drug discovery and detection and treatment of gastrointestinal diseases
US20030069404A1 (en) * 1996-11-14 2003-04-10 Rainer Haas Helicobacter antigens and corresponding DNA fragments
US20030023066A1 (en) * 1996-11-14 2003-01-30 Rainer Haas Helicobacter polypeptides and corresponding polynucleotide molecules
US6248551B1 (en) * 1997-03-28 2001-06-19 Institut Pasteur Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides
US5985631A (en) * 1997-09-12 1999-11-16 Oravax-Merieux Co. Method for preventing the activation of inactive, recombinant Helicobacter pylori apourease
WO2001083531A1 (en) * 2000-04-27 2001-11-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for identifying helicobacter antigens

Also Published As

Publication number Publication date
NO963508L (no) 1996-10-21
FI963281A7 (fi) 1996-10-22
EP0751786A4 (en) 1999-12-29
US20030007980A1 (en) 2003-01-09
NZ282535A (en) 2001-03-30
AU1968195A (en) 1995-09-11
AU694195B2 (en) 1998-07-16
EP0751786A1 (en) 1997-01-08
SK109496A3 (en) 1997-07-09
FI963281A0 (fi) 1996-08-22
CA2184057A1 (en) 1995-08-31
AU694195C (en) 2001-07-19
CZ250396A3 (en) 1996-12-11
WO1995022987A1 (en) 1995-08-31
US6290962B1 (en) 2001-09-18
FI963281L (fi) 1996-10-22
HU9602310D0 (en) 1996-10-28
PL179149B1 (pl) 2000-07-31
HUT75374A (en) 1997-05-28
OA10372A (en) 2001-11-14
JPH09509661A (ja) 1997-09-30
PL316007A1 (en) 1996-12-23
BR9506884A (pt) 1997-08-19

Similar Documents

Publication Publication Date Title
NO963508D0 (no) Ureasebasert vaksine og behandling av Heliobacter infeksjon
FI963696L (fi) Geeli ihosairauksien hoitoon ja ihon desinfiointiin
DE69302257D1 (de) Pilzhemmendes und hautheilungsförderndes Mittel
KR960008976A (ko) 처리장치 및 처리방법
DE69516989D1 (de) Externe Fixationsvorrichtung und Einrichtung
FI971969A0 (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
NO891896L (no) Fremgangsmaate og innretning for behandling av medisinsk spesialavfall.
NO920780L (no) Fremgangsmaate og anordning for behandling av epilepsi
NO971900D0 (no) Blandinger og behandling av multippel sklerose
FI930577A7 (fi) HIV-infektion rokote ja hoitomenetelmä
NO20014314L (no) Blandinger og metoder for behandling av stafylokokkisk infeksjon
NO931779D0 (no) Fremgangsmaate for behandling av kondensater av ammoniakk og urea
FI965204A0 (fi) Bromelaiinin lääkekäyttö
FI951060L (fi) Formulaatioita ja hoitomenetelmiä
NO951825D0 (no) Vannbasert hårbehandlingspreparat og anvendelse av dette
ID21874A (id) Penggunaan 1-hidroksi-2-piridon untuk pengobatan infeksi urap kulit
FI963638A0 (fi) Menetelmiä HIV-1-injektion diagnosoimiseksi ja hoitamiseksi
DE59306085D1 (de) Haar- und körperbehandlungsmittel
NO965591D0 (no) Kombinasjonsbehandling av HIV-infeksjon
NO985068L (no) Vaksiner for behandling av lymfom og leukemi
NO953003D0 (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
FI963263A0 (fi) Bromelaiinin lääkinnällinen käyttö
NO953002D0 (no) Anvendelse av eliprodil og enantiomerer derav for fremstilling av medisinske preparater
NO20013464D0 (no) Anvendelse av 3-isoksazolidinoner og hydroksylaminsyrer for behandling av infeksjoner
NO20022990L (no) Fremgangsmåte og sammensetning for behandling av smerte

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application